NSE · Basic Materials · Specialty Chemicals
EPS came in at 7.02 against a street estimate of 5.90 — a beat of 19.0%.
with an average price target of ₹575.50.
CONFIDENT Rossari delivered record Q2 revenue and EBITDA, led by volume growth, exports and value-added products. Margins improved sequentially despite freight and raw-material pressure, while debt and working capital declined. Q2 FY27 Exports grew 34% year-on-year and 75% quarter-on-quarter, led by HPPC and textiles. Target is at least 30% of full-year revenue from exports. Analysts focused on export mix, margin recovery, EO availability, capacity utilisation, Saudi Arabia timing and capital allocation. Management highlighted freight pressure, value-added products, phased expansion and debt reduction. 2026-10-19…
Full summary in the app.
| Holder | Stake |
|---|---|
| UTI Aggressive Hybrid Fund | 6.36% |
| Life Insurance Corporation of India | 4.01% |
| Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund | 1.85% |
| Bhupesh Kumar Lodha | 1.08% |
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 ROSSARI BIOTECH LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Consolidated Revenue: Rs 697.2 crore (Q1 FY27), up 28.2% YoY from Rs 543.7 crore (Q1 FY | 2026-07-19 |
| Annual report FY2026 ROSSARI BIOTECH LIMITED ANNUAL REPORT 2025-26 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Revenue from operations: ₹23,963.65 million (FY 2 | 2026-06-27 |
| Investor presentation · Q4 FY26 ROSSARI BIOTECH LIMITED – Q4 & FY26 RESULTS SUMMARY HEADLINE NUMBERS • FY26 Revenue: Rs. 2,396.4 cr (up 15.2% YoY from Rs. 2,080.3 cr in FY25) • FY2 | 2026-04-28 |
| Investor presentation · Q3 FY26 ROSSARI BIOTECH LIMITED – Q3 & 9M FY26 RESULTS SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue from Operations: Rs 581.7 crore (up 13% YoY vs Rs 512.7 cr | 2026-01-18 |
| Investor presentation · Q2 FY26 ROSSARI BIOTECH LIMITED – Q2 & H1 FY26 SUMMARY HEADLINE NUMBERS • Q2 FY26 Revenue: Rs. 586.1 crore (up 18% year-on-year, up 8% quarter-on-quarter) • | 2025-10-16 |
| Investor presentation | 2025-07-20 |
| Annual report FY2025 ROSSARI BIOTECH LIMITED – FY2024-25 SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹20,802.94 million (FY2024: ₹18,305.58 million) – growth of | 2025-06-06 |
| Investor presentation | 2025-04-26 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.50 / share ex-date Jul 10, 2026 | 2026-07-10 |
| Announcement | Date |
|---|---|
| Capacity addition update announced at subsidiary facility Update on Capacity Addition at the Subsidiary. | 2026-03-31 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rossari Biotech Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.